Previous 10 | Next 10 |
2024-02-02 12:31:34 ET More on Mid-day movers & stocks. CalAmp Corp. (CAMP) Q3 2024 Earnings Call Transcript Kopin: Visionary Leadership Fuels Growth And Market Potential Kopin Corporation (KOPN) Q3 2023 Earnings Call Transcript CalAmp GAAP EPS of -$2.27 ...
Pamrevlumab has now completed Stage 2 of the trial and topline data from this registration study in ~175 pamrevlumab treated patients is anticipated in 2Q 2024 Pamrevlumab is the first experimental arm to meet its required threshold for graduation in the seamless Phase 2/3 adaptive pl...
A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence ≥ 56 days with roxadustat vs. placebo (36.1% vs 11.5%; p=0.047 ǂ ). Dr. Moshe Mittelman’s presentation was sel...
2023-11-06 20:30:18 ET FibroGen, Inc. (FGEN) Q3 2023 Earnings Conference Call Nov 06, 2023, 05:00 PM ET Company Participants David DeLucia - Head of Corporate FP&A / Investor Relations Thane Wettig - Chief Executive Officer Juan Graham - Chief Financial Offic...
2023-11-06 16:07:23 ET More on FibroGen FibroGen Q3 2023 Earnings Preview FibroGen names Thane Wettig as permanent CEO Seeking Alpha’s Quant Rating on FibroGen Historical earnings data for FibroGen Financial information for FibroGen For...
Topline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision Promise SM Phase 2/3 study in metastatic pancreatic cancer Third quarter net revenue of $40.1...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
FibroGen Inc (FGEN) is expected to report $-0.68 for Q3 2023
NEW YORK, NY / ACCESSWIRE / October 27, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fibrogen, Inc. ("Fibrogen" or "the Company") (NASDAQ:FGEN). Investors who purchased Fibrogen securities prior to December 1, 2018, and continue to ho...
SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to fur...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that clinical data from the dose escalation porti...
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been select...
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Re...